in about 9% decline in topline with realizations improving by ~1% yoy. This was on the back of slight price hike taken by the management on BS IV implementation in January(much ahead of the BS IV implementation date) unlike its peers who took a hike at the fag end of the quarter. On the operating front, RM costs firmed up as RM to sales came in at 69.1% v/s 68% qoq and 66.6% yoy. EBITDA margins came in at 20% adjusted for CSR contribution of 740 mn....